Anti-HSV antibody

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent discloses a novel (potentially humanized) monoclonal antibody that specifically targets Herpes Simplex Virus (HSV) glycoprotein B, a highly conserved and critical component for viral replication and spread. The antibody not only neutralizes free HSV particles but also uniquely inhibits HSV cell-to-cell transmission, which is pivotal for effective disease control. The invention further covers pharmaceutical compositions, recombinant production systems, and the use of this antibody as a therapeutic or prophylactic agent against HSV-1 and HSV-2 infections, including drug-resistant strains.

Use CasesContent extracted from patent full text and abstract with AI.

• Treatment of HSV-1 (oral herpes) and HSV-2 (genital herpes) infections in humans.
• Prophylactic (preventive) therapy for at-risk individuals (e.g., immunocompromised patients, newborns, transplant recipients).
• Therapy for HSV-associated severe or recurrent diseases, such as herpes keratitis (eye infection), herpes encephalitis (brain infection), and neonatal herpes.
• Alternative or combination therapy for patients with HSV strains resistant to current antivirals like acyclovir or foscarnet.
• Adjunct therapy for individuals who are intolerant to standard antiviral drugs due to toxicity or contraindications.
• Manufacture of diagnostic agents or research tools for HSV-related studies through labeled antibody fragments.
• Potential veterinary applications for HSV infections in animals.

BenefitsContent extracted from patent full text and abstract with AI.

• Offers a therapeutic approach that targets and neutralizes both free viral particles and the direct cell-to-cell spread of HSV, which is not addressed by existing human immune responses or standard treatments.
• Reduced risk of resistance due to targeting a highly conserved region of glycoprotein B, essential for HSV infectivity and replication.
• Effective against acyclovir- and multi-drug-resistant HSV clinical isolates.
• Suitable for use in immunocompromised or otherwise contraindicated patients where conventional antivirals are less effective or cause severe side-effects.
• Likely to have lower immunogenicity and better tolerability in humans due to humanization of the antibody sequence.
• Potential use for both therapeutic and prophylactic (preventive) purposes.
• Can be produced in scalable recombinant systems and adapted for various delivery formats (full antibody or fragments, conjugated to drugs or labels).

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The invention relates to an anti-HSV antibody as defined in the claims, a pharmaceutical composition comprising of an effective amount of the said antibody, an expression vector comprising of a nucleotide sequence which encodes the said antibody, a host cell comprising of the said nucleotide sequence, a hybridoma cell capable of producing the said antibody and the use of the said antibody as a drug, in particular to use for the manufacture of a drug for the prophylactical or therapeutical treatment of HSV-associated diseases in a subject; as defined in the claims.